



LEADERSHIP AND BOARD OF DIRECTOR

Catherine Phillips, PhD
CEO/CSO

Dr. Catherine Phillips is, Co-founder and CEO/CSO of TargaCell Corporation, dedicated to developing a non-invasive efficient stem cell delivery technology from the bench to the bedside to improve cardiac repair, function, and quality of life for heart disease patients.

She has been a research scientist for 40 years, a biotech executive and entrepreneur, and an inventor on 6 issued patents related to stem cell and lymphocyte trafficking, detection technologies, and image analysis of protein patterns. Also, she served on V.A. and N.I.H. Small Business Innovative Research board study sections and several editorial boards for scientific journals.

Her interest in manipulating cell trafficking to improve the efficacy of cancer immunotherapies began at E. I DuPont de Nemours. Subsequently, she served as Associate Chief of Staff for Research & Development, Amarillo VA Medical Center; Assistant Dean for Research and Professor of Medicine, Texas Tech University; and Director of Research, Harrington Cancer Center. In addition, she was a Principal Investigator on an FDA-approved Phase 1/2 clinical immunotherapy trials for breast & ovarian cancer, which included in vivo trafficking of radiolabeled activated lymphocytes directed against tumor mucin expressed on breast & ovarian cancer cells. The proof-of-concept data for TargaCell's stem cell delivery technology for heart repair resulted from an academic-large pharma partnership.

Dr. Phillips earned a Ph.D. in Pathology & Immunology from the University of Florida and was a P.H.S. Fellow in Genetics at The Jackson Laboratory in Bar Harbor, Maine, and additional training at the University of Southern California & Los Angeles County Hospital, Molecular Pathology Practicum, sponsored by College of American Pathologists.